⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6174797 | 0.65 | — | — | |
| SCHEMBL27831840 | 0.64 | — | — | |
| SCHEMBL20602276 | 0.61 | KDM4E (0.33) | — | |
| SCHEMBL4879864 | 0.58 | — | — | |
| SCHEMBL4399067 | 0.58 | — | — | |
| SCHEMBL105524 | 0.54 | — | — | |
| SCHEMBL6850234 | 0.54 | — | — | |
| SCHEMBL21500439 | 0.53 | — | — | |
| SCHEMBL2407922 | 0.52 | — | — | |
| SCHEMBL6850203 | 0.52 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009003952-A2 | COLUMN AND METHOD FOR PREPARING A BIOLOGICAL SAMPLE FOR PROTEIN PROFILING | PRONOTA N.V. (BE) | 2009-01-08 | — | — | WO | claimed |
| EP-1478634-A4 | FURANONE DERIVATIVES | GALILEO PHARMACEUTICALS INC (US) | 2006-02-01 | — | — | EP | claimed |
| EP-1478634-A1 | FURANONE DERIVATIVES | Galileo Pharmaceuticals, Inc. (US) | 2004-11-24 | — | — | EP | claimed |
| US-6667330-B2 | Cytoprotective; neuroinflammation and neurodegenerative disorders; oxidative stress related conditions | GALILEO PHARMACEUTICALS, INC. | 2003-12-23 | — | — | US | claimed |
| US-20030176361-A1 | Furanone derivatives | MONSANTO TECHNOLOGY LLC | 2003-09-18 | — | — | US | claimed |
| WO-2003064403-A1 | FURANONE DERIVATIVES | GALILEO LABORATORIES, INC. (US) | 2003-08-07 | — | — | WO | claimed |
| WO-2024019936-A1 | NANOMATERIALS COMPRISING TRIOLS | BEAM THERAPEUTICS INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| CN-115554406-A | anti-CD 20 combinations for the treatment of tumors | 博笛生物科技有限公司 | 2023-01-03 | — | — | CN | disclosed |
| CN-115350279-A | anti-HER 2 combinations for the treatment of tumors | 博笛生物科技有限公司 | 2022-11-18 | — | — | CN | disclosed |
| CN-115337402-A | Combination therapeutic compositions and combination therapeutic methods for treating cancer | 博笛生物科技有限公司 | 2022-11-15 | — | — | CN | disclosed |
| CN-115252792-A | anti-EGFR combinations for the treatment of tumors | 博笛生物科技有限公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-114716555-A | Compounds and compositions for targeting EGFR expressing tumors | 博笛生物科技有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114671954-A | Compounds and compositions targeting HER2 positive tumors | 博笛生物科技有限公司 | 2022-06-28 | — | — | CN | disclosed |
| WO-2003028733-A1 | TETRACYCLIC INDOLE DERIVATIVES AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2003-04-10 | — | — | WO | disclosed |
| EP-1296982-A1 | 1-(HETEROARYL-PHENYL)-CONDENSED PYRAZOL DERIVATIVES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2002000655-A1 | 1 - (HETEROARYL-PHENYL) - CONDENSED PYRAZOL DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-01-03 | — | — | WO | disclosed |
| EP-0740679-A1 | CROSSLINKED POLYMERIC AMMONIUM SALTS | E.I. DU PONT DE NEMOURS & COMPANY INCORPORATED (US) | 1996-11-06 | — | — | EP | disclosed |
| EP-0730590-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-09-11 | — | — | EP | disclosed |
| EP-0691961-A1 | SUBSTITUTED CAPROLACTAMS AND DERIVATIVES THEREOF USEFUL FOR TREATMENT OF HIV DISEASE | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-01-17 | — | — | EP | disclosed |
| WO-1995019384-A1 | CROSSLINKED POLYMERIC AMMONIUM SALTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-07-20 | — | — | WO | disclosed |